Sun Pharma Advanced Research Company (SPARC), incorporated in 2006. is engaged in the pharmaceutical research and development.
The company’s core focus is innovation and new product development for global markets. SPARC undertakes projects in research and technology for new chemical entities (NCE’s) or new molecules, and novel drug delivery systems (NDDS).
NCE Projects- Under this the company is currently working in therapeutic areas namely anti-allergy, soft steroid, anticonvulsant and muscle relaxant.
It has developed SUN 1334 H molecule for anti allergy, which is in phase III clinical trails. It has developed SUN-S 461, an anti-inflammatory molecule, for use in the treatment of asthma / allergic rhinitis and COPD and will further enter clinical testing.
The lead molecule in anticonvulsant area, SUN-G 44, is a prodrug of the currently marketed drug gabapentin, which is used for the treatment of neuropathy and seizures and will further enter clinical testing. The company's muscle relaxant molecule SUN-B 09, is a prodrug of a currently marketed drug used as a skeletal muscle relaxant. SUN-B09 is currently in preclinical studies.
NDDS Projects- Under this the company is working on delivery system based platforms such as biodegradable implant, nanoemulsion, dry powder inhalation technology, wrap matrix controlled release systems and gastro retentive system for controlled release. The company is focused on innovating drug delivery technologies requires for treatment of cancers and psychiatric ailments.
SPARC has installed Tecnai Spirit cryo-transmission electron microscope (TEM) and three-dimensional (3D) tomography software developed by FEI Company. This will be used for quality control of drug-loaded vesicles to speed up the development of new therapeutics.